Amphastar Pharmaceuticals, Inc. plans to launch its generic version of Organon’s ganirelix acetate 0.25mg/0.5ml injectable during the current quarter ending 30 June, after receiving the second ever abbreviated new drug application approval for a product referencing the gonadotropin-releasing hormone antagonist.
The US-based player noted that the product was the company’s fourth injectable peptide product approval, including a US Food and Drug Administration nod at the end of 2020 for the first generic glucagon for injection emergency kit, 1mg